Gallbladder cancer - null regimens

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main gallbladder cancer page for current regimens.


Neoadjuvant therapy

No neoadjuvant therapy

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
In progress (ECOG-ACRIN EA2197) 2020-ongoing Phase III (C) Cisplatin & Gemcitabine (GC) In progress

No systemic therapy prior to surgery.

Subsequent treatment

References

  1. ECOG-ACRIN EA2197: NCT04559139

Metastatic or unresectable disease, all lines of therapy

Best supportive care

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Sharma et al. 2010 2006-2008 Randomized (C) 1. FUFA Did not meet primary endpoint of OS
2. mGEMOX Seems to have inferior OS

No active antineoplastic treatment.

References

  1. Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK, Thulkar S, Garg P, Chaudhary SP. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010 Oct 20;28(30):4581-6. Epub 2010 Sep 20. link to original article contains protocol PubMed